| Recent Press Releases can
also be found on the Home page.
RIVER EDGE, NJ July 2, 2009
Nephros Receives 510k Approval
for Dual Stage Ultrafilters
RIVER EDGE, NJ -March 31, 2009
Nephros Reports 2008 Fourth Quarter
and Full Year Financial Results
RIVER EDGE, NJ -February 24, 2009
Nephros provides update on 510k
application.
RIVER EDGE, NJ -Januaru 26, 2009
Nephros announced that its common stock
is now quoted in the Pink Sheets under
symbol "NEPH."
RIVER EDGE, NJ- January 14, 2009
Nephros Receives Notice of Intention to
Delist from AMEX RIVER EDGE, NJ- January 13, 2009
Nephros Receives 2009 Frost & Sullivan
Medical Device Patient Care Company
of the Year Award Press Release Archives
NEW YORK, November 20, 2008
Nephros Provides Corporate Update NEW YORK, November 14, 2008
Nephros Reports 2008 Third Quarter Results NEW YORK, September 18, 2008
Nephros Receives Non-Compliance Notification from AMEX NEW YORK, September 17, 2008
Nephros Appoints James S. Scibetta as Chairman of Board of Directors NEW YORK, September 17, 2008
Nephros Appoints Ernest A. Elgin III as President and Chief Executive
Officer NEW YORK, July 14, 2008
Nephros Exhibiting at Maryland ASHE Conference
July 20-23, 2008 NEW YORK, June 5, 2008
Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration
Products NEW YORK, June 2, 2008
Nephros exhibiting at Denver, Colorado APIC Conference
June 15-19, 2008 NEW YORK, May 10, 2008
Nephros to Exhibit at the XLV ERA-EDTA Congress in Stockholm, Sweden, May
10-13, 2008 NEW YORK, March 31, 2008
Nephros Reports 2007 Fourth Quarter and Full Year
Financial Results
NEW YORK, January 16, 2008
Nephros, Inc. Substantially Increases Stockholders' Equity and Expects
to Regain Compliance With the American Stock Exchange Continued Listing NEW YORK, December 19, 2007
Department of Defense Appropriations Act 2008 Provides
$2 Million for Continued Development of Nephros Dual Stage Ultra Reliable Filter
NEW YORK, November 20, 2007
Nephros Appoints James S. Scibetta to Board of Directors
Nephros Receives Approval to Market OLpur™ MD Hemodiafilter Series in
Canada NEW YORK, November 13, 2007
Nephros Reports Third Quarter 2007 Financial Results NEW YORK, October 16, 2007
Nephros Initiates Pivotal U.S. Trial for OLpur™ H2H™
Hemodiafiltration Module and OLpur™ MD 220 Hemodiafilter NEW YORK, October 3, 2007
Nephros Receives Non-Compliance Notification from Amex NEW YORK, September 25, 2007
Nephros Raises $12.7 Million in New Financing NEW YORK, August 13, 2007
Nephros Reports Second Quarter 2007 Financial Results
Revenues Increase 15%, Net Loss is Reduced NEW YORK, August 7, 2007
Nephros Discloses Nonpayment of Installment under the Lancer
Settlement Agreement in Current Report on Form 8-K
NEW YORK, July 20, 2007
Nephros Names New Independent Auditing Firm NEW YORK, May 23, 2007
Nephros Reports Departure of Director NEW YORK, May 16, 2007
Nephros to Initiate U.S. Clinical Trials NEW YORK, May 15, 2007
Nephros Reports First Quarter 2007 Financial Results
Revenues Increase 70%, Net Loss is Reduced NEW YORK, May 3, 2007
Nephros Provides Information Regarding Auditor's Going Concern
Report and Fiscal 2006 Results NEW YORK, May 1, 2007
Nephros Reports Departure of Director NEW YORK, March 1, 2007
Nephros Completes Informational Request from the FDA on
Investigational Device Exemption Application
Nephros MD and H2H Technologies Clinical Trials Expected to Commence in
March 2007 NEW YORK, January 29, 2007
Nephros Receives Conditional Approval from the FDA of Investigational
Device Exemption Application
Nephros MD and H2H Technologies Targeted to Begin Clinical Trials in First
Quarter 2007 NEW YORK, December 6, 2006
Italian Clinical Study Demonstrates Nephros’ Mid-Dilution HDF Therapy
As Optimal Treatment for Patients with Limited Vascular Access NEW YORK, November 20, 2006
American Stock Exchange Will Continue Nephros’s Listing NEW YORK, November 15, 2006
Nephros Reports Third Quarter 2006 Financial Results NEW YORK, October 23, 2006
Multi-Center Study Concludes Nephros Mid-Dilution Hemodiafiltration
Therapy Achieves Higher Clearance of Low Molecular Weight Proteins
Study Abstract Selected by Peer-Review Experts for Presentation
at American Society of Nephrology (ASN) Congress NEW YORK, October 5, 2006
Nephros Announces Positive Results of Clinical Study for Olpur MD190
Mid-Dilution Hemodiafiltration Filter
Study Findings to be Presented at October Nephrology Congress in Madrid NEW YORK, October 4, 2006
Nephros Selected for Development of Dual Stage Ultra Reliable
Portable Personal Water Filtration by U.S. Marine Corps ATD
$1 Million Department of Defense Appropriation Approved NEW YORK, August 22, 2006
Nephros Announces Restatement of Financial Statements NEW YORK, August 4, 2006
Nephros Selects Director William Fox to Serve as Executive Chairman
NEW YORK, July 21, 2006
Nephros Receives Non-compliance Notification from AMEX
NEW YORK, May 24, 2006
Nephros to Present at Dutton Associates' ''Recognizing Opportunity''
Health Sciences SmallCap Conference in San Francisco May 31
NEW YORK, January 13, 2006
Nephros Announces First Order from Major U.S. Hospital for Proprietary
Water Filtration System
NEW YORK, November 11, 2005
Nephros Reports Third Quarter 2005 Financial Results
NEW YORK, October 19, 2005
Nephros, Inc. to Present at the C.E. Unterberg Towbin Emerging
Growth Life Sciences Conference on October 26th
NEW YORK, August 15, 2005
Nephros Reports Second Quarter 2005 Financial Results
NEW YORK, July 8, 2005
Nephros, Inc. to Receive U.S. Patent for OLpūr™ H2H™
NEW YORK, June 17, 2005
Nephros Receives FDA Approval for its OLpūr™ HD190 High Flux Filter
NEW YORK, June 1, 2005
Nephros, Inc. Presenting at International Renal Conferences
NEW YORK, May 16, 2005
Nephros Reports First Quarter 2005 Financial Results
NEW YORK, April 26, 2005
Nephros Inc. Appoints Bernard Salick, M.D. To Board of Directors
NEW YORK, March 31, 2005
Nephros Reports Fourth Quarter and Year End Financial Results
NEW YORK, March 14, 2005
Nephros Announces 510(K) Filing with FDA for its OLpur™ HD190 High Flux Filter
NEW YORK, March 2, 2005
Nephros Enters into Hemodiafilter Manufacturing and Distribution Rights
Agreement with Asahi Kasei Medical
NEW YORK, December 23, 2004
Nephros Appoints Deloitte & Touche as Independent Registered Accounting Firm
NEW YORK, November 16, 2004
Nephros, Inc. Reports Third Quarter 2004 Financial Results
NEW YORK, November 11, 2004
Nephros, Inc. Announces Preliminary Evaluation Results for it's
OLpr™ MD190 Hemodiafilters at Dialysis Center in France
NEW YORK, September 22, 2004
Nephros, Inc. Announces Pricing of Initial Public Offering of it's Common Stock
NEW YORK, October 14, 2003
Nephros, Inc. Receives CE Mark Approval for the OLpr™ MD 190
|
